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Insulin, a pancreatic hormone produced by the beta cells of the
islets of Langerhans, tightly regulates glucose homeostasis by
promoting glucose uptake from plasma by peripheral tissues,
i.e. muscle and fat cells, and inhibiting hepatic glucose
production (DeFronzo et al., 1992). Insulin is stored inside
pancreatic beta cell secretory vesicles, in which six insulin
molecules form solid hexamers with two Zn2+ ions. This
crystalline structure is osmotically stable at pH 5.5 until
secretion (Dodson and Steiner, 1998; Emdin et al., 1980).
Typically, following postprandial hyperglycemia, the glucose
metabolism in beta cells induces an increase in the ATP/ADP
ratio, which triggers closure of ATP-sensitive potassium
channels (KATP). The resulting depolarization of the plasma
membrane then provokes influx of extracellular Ca2+,
activation of insulin-containing vesicle exocytosis and thus
secretion of insulin (Deeney et al., 2000; Rutter, 2001). The
secreted insulin is then carried through the circulation to
peripheral tissues, where insulin receptor activation stimulates
glucose uptake and utilization and/or storage as glycogen,
reducing blood glucose (Bjornholm and Zierath, 2005;
DeFronzo et al., 1985). Thus, insufficient insulin production
and/or defective glucose absorption in peripheral tissues can
lead to hyperglycemia, which, in some cases can be
compensated by hyperinsulinemia (Kahn, 1998). Development
of type 2 diabetes is characterized by a particular breakdown
of this system: hyperinsulinemia compensates for the
resistance to insulin in peripheral tissues that is found in the
early prediabetic state. The subsequent development of
hyperglycemia results from the failure of beta cells to secrete
enough insulin for effective compensation (Kahn, 1998).
Zinc is an important component for cell survival and
participates in structure and function of many proteins (Vallee
and Falchuk, 1993). It is necessary in fundamental cellular
mechanisms such as DNA replication, metabolic enzyme
activity and cellular protection against apoptosis and oxidative
stress (Chimienti et al., 2003). Moreover, zinc has a specific
role in some specialized cells, such as pancreatic beta cells in
which the zinc content is among the highest in the body
(Clifford and MacDonald, 2000). In these cells, zinc is
necessary to form zinc-insulin crystals in secretion vesicles
(Dodson and Steiner, 1998). Analyses of islets from 65Zn-
treated rats have shown that one-third of the total beta cell zinc
content is present within insulin granules. Extra-granular zinc
may act as a reservoir for granular zinc and may regulate
insulin synthesis, storage, and secretion (Figlewicz et al.,
Insulin-secreting pancreatic beta cells are exceptionally
rich in zinc. In these cells, zinc is required for zinc-insulin
crystallization within secretory vesicles. Secreted zinc has
also been proposed to be a paracrine and autocrine
modulator of glucagon and insulin secretion in pancreatic
alpha and beta cells, respectively. However, little is known
about the molecular mechanisms underlying zinc
accumulation in insulin-containing vesicles. We previously
identified a pancreas-specific zinc transporter, ZnT-8,
which colocalized with insulin in cultured beta cells. In this
paper we studied its localization in human pancreatic islet
cells, and its effect on cellular zinc content and insulin
secretion. In human pancreatic islet cells, ZnT-8 was
exclusively expressed in insulin-producing beta cells, and
colocalized with insulin in these cells. ZnT-8 overexpression
stimulated zinc accumulation and increased total
intracellular zinc in insulin-secreting INS-1E cells.
Furthermore, ZnT-8-overexpressing cells display enhanced
glucose-stimulated insulin secretion compared with control
cells, only for a high glucose challenge, i.e. >10 mM glucose.
Altogether, these data strongly suggest that the zinc
transporter ZnT-8 is a key protein for both zinc
accumulation and regulation of insulin secretion in
pancreatic beta cells.
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1984). The zinc/insulin ratio in secretory granules might
indicate that a certain level of zinc ions is needed to initialize
the crystallization of zinc-insulin hexamers (Sondergaard et al.,
2003). Furthermore, after glucose stimulation, large amounts
of zinc are secreted locally in the extracellular matrix together
with insulin (Qian et al., 2000). Recent studies have suggested
that this co-secreted zinc plays a role in islet cell paracrine
and/or autocrine communication: it activates KATP channels
(Franklin et al., 2005), thereby exerting a negative control on
the secretory process (Bloc et al., 2000), and regulating
glucagon secretion by alpha cells (Franklin et al., 2005;
Ishihara et al., 2003). Zinc may also contribute to beta cell
death by a paracrine mechanism (Kim et al., 2000). To control
these zinc-related mechanisms, a tight regulation of zinc
homeostasis and localization is ensured by zinc transporters;
two families have been described. The SLC39 family of
proteins (also named ZIP) allow the intracellular uptake of
zinc, whereas the SLC30 family (ZnT) ensures zinc efflux from
the cytosol to the extracellular matrix or intracellular organelles
(for a review, see Kambe et al., 2004). Among the ZnT family
of proteins, we previously identified ZnT-8, which was
detected solely in pancreatic islets (Chimienti et al., 2004). In
this study, we show that ZnT-8 protein is specifically expressed
in human islet beta cells and we further characterize this
transporter, including the determination of its membrane
topology and zinc accumulation ability in beta cells. We show
that overexpression of ZnT-8 in the rat insulinoma INS-1E cells
significantly protected cells against zinc-depletion-induced cell
death and enhanced glucose-stimulated insulin secretion only
in high-glucose conditions. Converging evidence supports the
hypothesis that ZnT-8 is a major component of the insulin
synthesis/secretion pathway and may thereby constitute a novel
pharmacological target for the treatment of diabetes.
Results
Tissue specificity of ZNT8 gene expression
We have previously shown that ZNT8 mRNA was specifically
expressed in human islets (Chimienti et al., 2004), and
identified the ortholog of this transcript in other mammals
species, including mouse (Seve et al., 2004). In this work we
used expression microarrays to assess the tissue specificity of
ZNT8 mRNA expression in the mouse. As shown in Fig. 1, a
strong signal was observed in pancreatic islets, whereas no
signal was observed in other tissues tested, including exocrine
pancreas. This confirmed in mouse the islet-specific expression
of ZNT8 found in human at the mRNA level.
In agreement with the mouse data, expression of the ZnT-8
protein in human islets was demonstrated with an antibody
directed against human ZnT-8 (Fig. 2A, lane 4). A negative
control was performed on HeLa-EGFP expressing cells,
because HeLa cells were shown not to express ZNT8 mRNA
(Chimienti et al., 2004). No signal was observed in the negative
control, indicating that no other ZnTs expressed in HeLa
cells were recognized by our antibody. A positive control
was performed on HeLa-ZnT-8-EGFP-expressing cells. We
observed a band at the expected molecular weight for the
fusion protein. However aggregates were often noticeable at
high molecular weights. This may indicate post-translational
modifications or aggregation of the protein, a phenomenon
often observed with membrane proteins (Sagne et al., 1996),
and already observed for ZnT-4 (Michalczyk et al., 2002).
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ZNT8 mRNA is expressed in INS-1E cells (Chimienti et al.,
2004). However the rat isoform of the protein was not
recognized (Fig. 2A, lane 3), indicating a good species-
specificity of the antibody despite high sequence homology. In
human pancreatic islet extracts, we observed one band
corresponding to ZnT-8. We also demonstrated by
immunohistochemistry using human islet cytospins, that ZnT-

























































Fig. 1. Expression of ZNT8 mRNA in mouse tissues. ZNT8 mRNA
expression was assessed by expression microarrays (Affymetrix)
using RNA extracted ex vivo from mouse pancreatic islets,
panreactic acini, pituitary, brain, adrenal gland, liver, skeletal muscle,
epididymal adipose tissue, lung, kidney and spleen.
Fig. 2. Expression of ZnT-8 in human islets at the protein level.
(A) Western blot with anti-human ZnT-8 antibody showing the
presence of the protein in total extracts of human pancreas. Lane 1,
HeLa ZnT-8-EGFP (positive control); lane 2, HeLa-EGFP (negative
control); lane 3, rat insulinoma INS-1E cells; lane 4, human
pancreatic islet extracts. (B) The ZnT-8 protein is detected (red) by
immunochemistry of pancreatic islet cells. Nuclei were












4201ZnT-8 enhances insulin secretion in INS-1E cells
Double immunostaining and confocal microscopy analysis
of human islet cytospins revealed that insulin localization
(green) completely coincides with that of ZnT-8 (red), thus
confirming the colocalization between these two proteins in
vivo (Fig. 3). A blind observer manually counted the number
of insulin-positive, ZnT-8-positive and doubly positive cells as
well as total cell number in 40 randomly selected fields.
Among the 1015 cells counted, 465 cells were found positive
for ZnT-8 and 459 cells were positive for insulin, all of which
were also positive for ZnT-8. The insulin+/ZnT-8+ ratio was
found to be 98.7%, indicating that ZnT-8 is exclusively
expressed in pancreatic beta cells.
Overexpression of ZnT-8-EGFP in cultured cells
We generated ZnT-8-EGFP and control EGFP-expressing INS-
1E stable cell lines and checked the presence of the fusion
protein in INS-1E cells by western blot using an anti-ZnT-8
antibody. Fig. 4A shows a typical experiment obtained with
total protein extracts in ZnT-8-EGFP-expressing or control
INS-1E-EGFP cells. We observed one band at the expected
molecular weight for INS-1E cells expressing ZnT-8-EGFP,
which was not present in EGFP-expressing cells. Specificity of
immunoblot procedure was also verified using anti-GFP
antiserum (not shown). To precisely localize the fusion protein
in INS-1E cells, we used confocal fluorescence microscopy.
Cells displayed punctuated staining, consistent with insulin co-
localization (Fig. 4B, left). A high magnification image of the
same cell (Fig. 4B, right) showed that ZnT-8-EGFP mainly
localized to granules in close proximity to the plasma
membrane. We also observed slight membrane staining in
some adjacent cells (Fig. 3C), suggesting the possible presence
of ZnT-8 at the plasma membrane after fusion of the insulin-
containing granules. Thus, our cell models stably expressed
either the fusion protein ZnT-8-EGFP or EGFP and were used
in subsequent experiments.
ZnT-8 membrane topology
To address the plasma membrane topology of ZnT-8, we used
antibodies 9A or 9B directed against either amino acids 355-
359 or 34-49 of the human ZnT-8 protein, respectively, for
immunolabeling of both permeabilized and non-permeabilized
ZnT-8-EGFP-expressing INS-1E cells. As shown in Fig. 5A,
the ZnT-8-EGFP signal completely superimposed with anti-
ZnT-8 staining in permeabilized cells, whereas non-
permeabilized cells displayed only ZnT-8-EGFP fluorescence.
Because only extracellular epitopes can be immunolabeled in
non-permeabilized cells, this indicates that both the N- and C-
termini of ZnT-8 are intracellular when the protein is present
at the plasma membrane level (Fig. 5B). The same results have
been obtained with HeLa cells (not shown), which do not have
a secretory pathway and thus express ZnT-8-EGFP mainly at
the plasma membrane level.
Cellular zinc content
Zinc concentration in all buffers and media used was
determined. Lysis buffer contained very low amounts of zinc,
i.e. 1.4 g/l (20 nM), whereas normal complete culture
medium contained 176 g/l zinc (2.7 M); a value falling
within the range reported by other studies (Sondergaard et al.,
2005). Conversely, zinc-supplemented medium contained
6175 g/l zinc, corresponding to 94 M Zn2+, which is a high
but non-toxic dose for INS-1E cells (see below). Therefore,
the low zinc content in the lysis buffer is unlikely to interfere
with the zinc contained in samples, and the zinc-
supplemented media, while non-toxic, contained much more
zinc than normal medium. In these conditions, zinc
supplementation did not increase total zinc content in control
cells (Fig. 6A). By contrast, ZnT-8-expressing cells contained
significantly more zinc than control cells in normal conditions
(830±109 g Zn/g protein for control cells vs 1072±78 g
Zn/g protein for ZnT-8-expressing cells, P<0.01). Contrary
to control cells, zinc supplementation of ZnT-8-EGFP-
expressing cells further increased total cellular zinc (1334±80
g Zn/g protein vs non-supplemented cells, P<0.05).
Therefore, it appears that ZnT-8 overexpression, rather than
zinc supplementation alone, significantly increased zinc
accumulation ability and total cellular zinc content in INS-
1E cells.
Fig. 3. Colocalization of ZnT-8 and insulin in human islet cells. Analysis of islet cell cytospins using anti-insulin and anti-ZnT-8 antibodies by
confocal fluorescence microscopy. Insulin (green, left) displayed a characteristic punctuate staining. ZnT-8 staining (red, middle) completely
coincided with the staining of insulin. Superimposition of the two images demonstrates the colocalization of ZnT-8-GFP and insulin (yellow,













Protection against zinc depletion by ZnT-8
overexpression
We next further investigated the capability of ZnT-8 to act on
zinc metabolism by measuring cell viability after incubation
with different concentrations of either zinc sulphate or the zinc
chelator TPEN (Fig. 6B,C). There were no differences in zinc
toxicity between control and ZnT-8 expressing cells. The
calculated LC50 (concentration with 50% viability) was 482±8
M and 510±8 M zinc sulphate in control and ZnT-8-
expressing cells, respectively (P>0.1). We then investigated
the effect of zinc depletion and observed that ZnT-8
overexpression conferred resistance to zinc depletion (Fig. 6C).
Compared with control cells, which have a LC50 for TPEN of
4.59±0.09 M, ZnT-8 expressing cells were protected from the
toxicity of the zinc chelator TPEN, with a LC50 of 6.66±0.09
M (P<0.0001). Thus, overexpression of ZnT-8 did not have
any effect on zinc toxicity, but significantly protected INS-1E
cells from zinc-depletion-induced cell death.
Enhanced insulin secretion by ZnT-8 overexpression
To assess a potential role for ZnT-8 in insulin synthesis and/or
secretion, we used INS-1E cells, which were shown to be a
stable and valuable beta-cell model for insulin secretion
(Merglen et al., 2004), stably transfected with human ZnT-8-
EGFP. Since expression of EGFP alone did not produce any
change in glucose-stimulated insulin secretion compared with
parental INS-1E cells (data not shown), these cells were used
to measure insulin secretion after glucose stimulation.
Compared with insulin release in normal conditions, i.e. 5.6
mM glucose, exposure of INS-1E-EGFP cells to 15 or 20 mM
glucose resulted, as expected, in a significant increase of
insulin secretion with a plateau phase after 15 mM glucose
(Fig. 7). Overexpression of ZnT-8 did not lead to a significant
increase in insulin release in basal conditions, nor did it
significantly change the cellular insulin content (1.3±0.1
g/million cells for control cells vs 1.2±0.1 g/million cells
for ZnT-8 overexpressing cells, P>0.5), which are values in the
range found in the study describing INS-1E cells (Merglen et
al., 2004). However, when incubating the cells at high glucose
concentrations, insulin secretion in ZnT-8-expressing cells was
significantly increased, almost twice as much as control cells.
This was not attributable to a change in the storage pool,
because data were expressed as percentage of insulin content.
Moreover the plateau phase at about 15-20 mM glucose,
previously described in INS-1E cells (Merglen et al., 2004),
persisted in ZnT-8 expressing cells. Therefore it appears that
overexpression of ZnT-8 in INS-1E cells enhanced glucose-
induced insulin secretion only in high-glucose conditions.
Discussion
Zinc is concentrated in islets cells and is related to insulin
synthesis, storage and secretion (Zalewski et al., 1994). We
previously identified the zinc transporter ZnT-8, whose mRNA
was solely detected in pancreatic islet cells (Chimienti et al.,
2004). In this study we show that ZNT8 mRNA expression was
also restricted to pancreatic islet cells in mouse, and that the
ZnT-8 protein is expressed in human islet cells in vivo.
Moreover, in human pancreas, ZnT-8 was detected by confocal
microscopy only in islet insulin-producing beta cells, and co-
localized with insulin in these cells. ZnT-5 has been
hypothesized to play a role in transporting zinc into secretory
granules (Kambe et al., 2002). However, its expression seems
ubiquitous (Seve et al., 2004) and functional studies suggest
that this transporter rather participates in zinc loading to apo-
proteins in the Golgi apparatus (Suzuki et al., 2005). Indeed,
ZnT-8 seems to be the only ZnT expressed exclusively in
pancreatic beta cells and thus may be of prime importance for
insulin secretory pathway.
In INS-1E cells, ZnT-8 has been shown by confocal
microscopy to be present in granules that are in close proximity
to the plasma membrane and, to a lesser extent, at the plasma
membrane level. To date, predictions of the membrane
topology of the ZnT family of proteins were only done in
silico. Moreover, most of the programs used predicted the ZnT
proteins to have six transmembrane domains, however, some
algorithms underline the putative presence of a seventh
transmembrane domain (Hirokawa et al., 1998). Therefore four
models were possible for ZnT-8 membrane topology: two
models with six helixes, the N- and C-termini domains facing
either the extracellular or the cytosolic side. In the other two
models, the presence of seven transmembrane domains implies
that N- and C-termini are not located at the same side of plasma
membrane. Our experimental data are in accordance with most
of predicted models and consistent with the zinc export
Journal of Cell Science 119 (20)
Fig. 4. ZnT-8 overexpression is INS-1E cells. (A) Western blot with
anti-human ZnT-8 antibody showing the presence of the fusion
protein at the expected size (i.e. 67 kDa) in ZnT-8-expressing cells
but not in control EGFP-expressing cells. (B) Confocal fluorescence
microscopy of ZnT-8-EGFP-expressing INS-1E cells. A
representative cell displaying punctuated staining consistent with
insulin colocalization. The panel on the right is a magnified image of
the selected area of the cell on the left, showing that ZnT-8-EGFP is
mainly localized in granules in close proximity to the plasma
membrane. (C) Fluorescence microscopy of ZnT-8-expressing cells.
Arrows indicate localization of ZnT-8-EGFP at the plasma











4203ZnT-8 enhances insulin secretion in INS-1E cells
function of the ZnT family, and with the function of ZIP family,
which are zinc uptake transporters whose extremities are
located outside the cell (Mathews et al., 2005). Furthermore,
this membrane topology of zinc export transporter is also
consistent with a role for ZnT-8 in exporting zinc from the
cytoplasm to insulin-containing vesicles.
In agreement with previous findings in HeLa cells
(Chimienti et al., 2004), ZnT-8 acts as a zinc transporter in
INS-1E cells, because its overexpression augments total
cellular zinc. Surprisingly, zinc supplementation did not
increase total zinc in control cells. This reflects the fact that
beta cells, as is the case with prostate cells (Costello et al.,
2004), already contain very high amounts of zinc compared
with other cell types. However, zinc at high concentrations can
be toxic for cells, and may even actively participate in islet cell
death under certain conditions (Kim et al., 2000). Indeed, the
LC50 for zinc was about 490 M in INS-1E cells. This is much
higher than other cell types, including HeLa cells, which have
a LC50 for zinc of 142 M (Devergnas et al., 2004). It has been
suggested that beta cells need to contain sufficient amounts of
zinc for proper function and formation of insulin hexamers
(Sondergaard et al., 2003). Therefore, added extracellular zinc
may not be able to get in the cells, or may be extruded from
cells. However, ZnT-8 overexpression enhanced the capacity of
the cell to store zinc, demonstrating that the zinc
transport/storage capacity, rather than extracellular zinc status,
is important for zinc accumulation in beta cells. As a
consequence, zinc toxicity is not modified by ZnT-8
overexpression. However, because they store more zinc, ZnT-
8-expressing cells were protected from zinc depletion-induced
cell death compared with control cells.
In diabetes, hypozincemia is a common feature (Garg et al.,
1994; Roussel et al., 2003). Zinc supplementation can
significantly inhibit the development of type 1 diabetes (Ho et
al., 2001), and markedly improve the hyperglycemia of
streptozotocin-induced diabetic mice (Chen et al., 2000). Zinc
has also demonstrated protective effects in type 2 models of
diabetes (for a review, see Taylor, 2005). Zinc supplementation
has been found to be effective for reducing fasting
hyperglycemia and hyperinsulinemia, and reducing weight
gain in young db/db mice (Simon and Taylor, 2001). Beneficial
antioxidant effects of zinc supplementation have been found in
people with type 2 diabetes (Anderson et al., 2001). Excessive
apoptosis of pancreatic beta cells has been associated with
diabetes (for a review, see Chandra et al., 2001). Zinc depletion
by itself is a well-known inducer of apoptosis (Chimienti et al.,
2001), but can also promote oxidative stress-induced apoptosis
(Baynes, 1991), thereby participating in decreased in beta cell
mass. In addition, some studies suggest that cells with deprived
zinc stores are less able to defend themselves against oxidative
Fig. 5. Determination of ZnT-8 membrane topology.
(A) Confocal microscopy images of INS-1E-ZnT-8-
EGFP cells, incubated with anti-ZnT-8 antibodies 9A or
9B (see Materials and Methods) before or after
membrane permeabilization. The EGFP signal is present
in both permeabilized and non-permeabilized cells,
whereas antibodies recognize the ZnT-8 protein only
after permeabilization. Bars, 15 m. (B) Proposed
model for the membrane topology of ZnT-8. Gray boxes
indicate location of antibody epitopes, 9A, 9B. HIS,













injuries, underlining the antioxidant properties of zinc
(Chausmer, 1998). Therefore, enhancing the capacity of beta
cells to store zinc may help to protect the pancreas against zinc
depletion and/or oxidative stress frequently observed in
diabetes.
Forty years ago, Quarterman et al. demonstrated that zinc-
deprived rats had an impaired insulin secretion response to
glucose stimulation (Quarterman et al., 1966), and other
studies indicated decreased islet cell insulin content in zinc-
deficient states (Engelbart and Kief, 1970). In this study, total
insulin was not significantly increased in ZnT-8-expressing
cells despite higher zinc content, nor was insulin secretion in
basal glucose conditions. However, in stimulating glucose
conditions, corresponding to hyperglycemia, overexpression of
ZnT-8 significantly increased insulin secretion, to almost twice
that of control cells, and the plateau phase observed after 15
mM glucose in INS-1E cells was still present. Thus, the
increase in insulin secretion induced by ZnT-8 overexpression
is glucose dependent. Altogether these results strongly suggest
that ZnT-8 enhances zinc storage in insulin granules and is
directly implicated in the insulin secretion pathway. Zinc
transporters are a growing field of study, and such a role for
ZnT-8 is not surprising in the light of the importance of the
function of ZnT-3 in zinc-rich vesicles in the brain (for a
review, see Frederickson et al., 2005).
In summary we demonstrate that the ZnT-8 protein is
expressed only in pancreatic beta cells in vivo. In cultured
cells, overexpression of ZnT-8 augmented total cellular zinc
content, thus protecting cells from zinc depletion and enhanced
insulin secretion under hyperglycemic conditions, suggesting
that ZnT-8 has a major role in the insulin secretion pathway.
Triggering ZnT-8 expression and/or activity may be an
interesting approach in the treatment of type 2 diabetes, in
which the zinc depletion frequently observed is likely to
participate in beta-cell mass decrease.

































































Fig. 6. Effect of extracellular zinc concentration on zinc content and
cell viability. (A) Zinc concentrations in cells were measured by
electrothermal atomic absorption spectrophotometry in either normal
or zinc-supplemented medium. Values are expressed as zinc
concentration normalized for protein content. *P<0.01 vs control;
**P<0.05 vs non-supplemented cells. White bars, control cells; gray
bars, INS-1E-ZnT8-EGFP cells. (B) After incubation with different
concentrations of zinc sulphate, the cell viability was determined by
MTT assay. Values are the mean ± s.e.m. of at least ten independent
experiments White bars, control cells; gray bars, INS-1E-ZnT8-
EGFP cells. (C) After incubation with different concentrations of the
zinc chelator TPEN, the cell viability was determined by MTT assay.
Values are the mean ± s.e.m. of at least ten independent experiments.
*P<0.05 vs control; **P<0.005 vs control. White bars, control cells;

































Fig. 7. Influence of ZnT-8 on glucose-induced insulin secretion.
INS-1E-EGFP and INS-1E-ZnT-8-EGFP cells were used to assess
insulin secretion in response to glucose. After incubation in glucose-
free buffer (see Materials and Methods), cells were exposed to
different concentrations of glucose for 30 minutes. Intracellular and
secreted insulin were measured by ELISA. White bars, control cells;
gray bars, INS-1E-ZnT8-EGFP cells. Values are the mean ± s.e.m.













4205ZnT-8 enhances insulin secretion in INS-1E cells
Materials and Methods
Chemicals
All chemicals were reagent grade from Sigma (St Quentin-Fallavier, France) or
Merck (Grenoble, France).
ZNT8 mRNA expression analysis in mouse
The tissue distribution of mRNA encoding ZnT-8 in the mouse was studied in male
C56Bl6 mice (8-12 weeks of age). Total RNA was extracted ex vivo from mouse
pancreatic islets, panreactic acini, pituitary, brain, adrenal gland, liver, skeletal
muscle, epididymal adipose tissue, lung, kidney and spleen using TRIzol Reagent
according to the manufacturer’s protocol (Gibco BRL, Carlsbad, CA, USA),
followed by a cleanup procedure with RNeasy columns (Qiagen, Cologne,
Germany). In addition, total RNA from fresh collagenase-isolated mouse pancreatic
islets and pancreatic acini, hand-selected under a dissecting microscope in ice-cold
media, was extracted using the Absolutely RNA microprep from Stratagene. The
total RNA quantity and quality was determined using the NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE) and the 2100
Bioanalyzer (Agilent, Waldbronn, Germany), respectively. Total RNA profiles of all
tested samples were similar with sharp 18S and 28S rRNA peaks on a flat baseline.
RNA quantification was performed using Affymetrix mouse 430 2.0 expression
microarrays (Affymetrix, Santa Clara, CA). Biotin-labeled cRNA was labeled
overnight and fragmented for 35 minutes at 94°C; concentration and quality of
labeled cRNA was measured, respectively, with the NanoDrop ND-1000 and
Bioanalyzer 2100. Fragmented cRNA was hybridized onto the 430 2.0 arrays for
16 hours at 45°C, followed by washing and staining in the Fluidics Station
(Affymetrix) and Scanning using a 3000 GeneScanner. Raw data were analyzed
using GCOS software. Signal intensities were scaled using the global scaling
method taking 150 as target intensity value. For all tissues, three independent
biological replicates were studied; islets and pituitaries were studied with n=5 per
condition.
Cell culture methods
Aliquots of the INS-1E cell line were a gift from Dr P. Maechler (Geneva,
Switzerland). INS-1E cells were grown at 37°C in a 5% CO2-enriched atmosphere
in RPMI 1640 medium (Invitrogen, France) including 10% heat-inactivated fetal
bovine serum (Invitrogen, France), 50 M 2-mercaptoethanol, 1 mM sodium
pyruvate, 10 mM HEPES, 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml
streptomycin and routinely split at a 1:5 ratio.
HeLa epithelial cells (ATCC number CCL-2) were grown at 37°C, in a 5% CO2-
enriched atmosphere, in Opti-MEM medium (Modified Eagle’s Medium,
Invitrogen) supplemented with 5% heat-inactivated fetal calf serum, 2 mM
glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin.
Plasmid construction and generation of stable cell lines
The cloning of pZnT-8-EGFP has been described elsewhere (Chimienti et al., 2004).
ZnT-8-EGFP- and control EGFP-expressing INS-1E stable cell lines were generated
by transfecting pZnT-8-EGFP or pEGFP into INS-1E cells using Lipofectamine
Plus (Invitrogen, France). The stable cell lines were selected by culturing the cells
in the medium containing G418 (350 g/ml) and cloned using a cell sorter. Selected
clones were maintained with G418 (200 g/ml). After amplification, the expression
of the fusion protein was controlled by fluorescence microscopy; size and specificity
of the fusion product were verified by western blot.
Western blot analysis
Samples were resolved by 10% SDS-PAGE, transferred onto nitrocellulose
membranes, and immunoblotted with the specified antibody followed by an
appropriate horseradish peroxidase (HRP)-conjugated secondary antibody. Western
blot signal was developed according to standard procedures using ECL (GE
Healthcare).
ZnT-8 localization in human islets
Human pancreases were harvested from non-diabetic, non-obese brain-dead donors
(n=3) in accordance with French regulations and after approval of Lille 2 University
ethical committee. Pancreatic islets were isolated after ductal distension of the
pancreases as described (Lukowiak et al., 2001). Human islets were washed with
PBS and centrifuged (200 g). Cell dissociation was achieved using Splitase®
(Autogen Bioclear, UK) for 3 minutes. and stopped by addition of culture medium.
Cytospins were made with cell suspension and fixed in 1% paraformaldehyde.
Immunocytochemistry was performed on islet cell cytospins.
Cells or cytospins were permeabilized in PBS containing 0.1% Triton X-100 and
then blocked in 2% BSA in PBS for 1 hour. Primary antibodies [i.e. rabbit anti-
ZnT-8 (1:10 dilution) combined or not with mouse anti-insulin (1:2000 dilution)]
diluted in fresh blocking buffer were then added. After washing, cells were either
revealed with Phtalocyanine Red (Histomark Red, Kirkegaard and Perry
Laboratories, Gaithersburg, MD) and nuclei were counterstained with Carazzi’s
hematoxylin for colorimetric studies or incubated with sheep anti-mouse IgG-FITC
conjugate and goat anti-rabbit-Cy3 secondary antibodies (GE Healthcare) for
fluorescence studies. Coverslips were mounted onto glass slides using FluorSave
(Calbiochem, La Jolla, CA) and photographed using a Leica confocal fluorescence
microscope.
Membrane topology of ZnT-8
Immunolabeling of cultured cells for determination of membrane topology was done
essentially as described previously (Mathews et al., 2005). Briefly, pZnT-8-EGFP
expressing INS-1E cells were seeded onto glass coverslips and allowed to attach for
72 hours before fixation in 4% formaldehyde in PBS. After washing with 0.25%
NH4Cl in PBS, the cells were permeabilized in PBS containing 0.1% Triton X-100.
Cells were then blocked in 2% BSA in PBS for 1 hour, followed by the addition of
anti-ZnT-8 antibodies 9A or 9B, directed against amino acids 355-359 or 34-49 of
the human ZnT-8 protein, respectively. Cells were washed in blocking buffer then
incubated in donkey-anti-rabbit IgG-Cy3 conjugate, diluted in blocking buffer at
1:300. Cells were washed in PBS followed by a final wash in ddH2O. For
immunolabeling without permeabilization, cells were incubated with primary
antibody in PBS containing 0.1% bovine serum albumin for 30 minutes before
fixation. Cells were then washed in PBS, and fixation and secondary antibody
labeling were conducted as with permeabilized cells.
Importance of ZnT-8 for intracellular zinc content
For intracellular zinc determination assays, INS-1E-EGFP- and INS-1E-ZnT-8-
EGFP-expressing cells were supplemented with 90 M ZnSO4 or not until 80%
confluency. Cells were then trypsinized and washed three times in Ca/Mg-free PBS.
The subsequent pellet was resuspended in 900 l lysis buffer (1% Triton X-100 in
10 mM Tris-HCl pH 7.4) and cells were lysed by three cycles of freeze-thawing.
Zinc concentrations were determined on total extracts by electrothermal atomic
absorption spectrophotometry (Perkin-Elmer, USA) and normalized for protein
content (BCA assay).
Zinc and zinc-depletion induced cell death
Cells were plated in 96-well plates and allowed to attach for 24 hours. Cells were
then treated by the indicated dose of either zinc sulphate or the zinc chelator
N,N,N,N-tetrakis(2-pyridylmethyl)-ethylenediamine (TPEN) for 24 hours at
37°C. 24 hours after treatment, cellular viability in the presence or absence of
experimental agents was determined using the MTT assay (Carmichael et al., 1987).
Briefly, following experimental treatment, a final concentration of 0.5 g/ml MTT
was added to each well, and the plate was incubated in the dark for 3 hours at 37°C.
The medium was then removed, and the coloured reaction product was solubilized
in 100 l DMSO. Absorbance was measured at 570 nm using a Vmax plate reader
(Labsystems Multiskan RC). The percentage viability was calculated as follows:
percentage specific viability=[(A–B)/(C–B)]100 where A=OD570 of the treated
sample, B=OD570 of the medium, and C=OD570 of the control (phosphate buffer
saline (PBS)-treated cells). The values were expressed as percentage viability
relative to vehicle-treated control cultures.
Insulin secretion
Insulin secretion was assessed on INS-1E-EGFP- and INS-1E-ZnT-8-EGFP-
expressing cells. The secretory responses to glucose were tested as described before
(Merglen et al., 2004). Briefly, cells were maintained for 2 hours in glucose-free
culture medium. The cells were then washed twice and preincubated for 30 minutes
at 37° C in glucose-free Krebs-Ringer bicarbonate HEPES buffer (KRBH: 135 mM
NaCl, 3.6 mM KCl, 5 mM NaHCO3, 0.5 mM NaH2PO4, 0.5 mM MgCl2, 1.5 mM
CaCl2, and 10 mM HEPES, pH 7.4). BSA (0.1%) was added as an insulin carrier.
Cells were subsequently washed with glucose-free KRBH and then incubated for
30 minutes at 37°C in KRBH containing different concentrations of glucose. The
reaction was stopped by placing the plates on ice; supernatants were collected to
determine insulin secretion and cells were used for intracellular insulin content
following acid-ethanol extraction. Insulin was measured by ELISA (Linco)
according to the manufacturer’s instructions.
Statistics
All data were expressed as mean ± s.e.m. Statistical analysis was by two-tailed,
unpaired Student’s t-test, and differences were considered significant when P<0.05.
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